Stock Price Forecast

March 27, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Compass Therapeutics Inc chart...

About the Company

compass therapeutics is an antibody discovery and development company focused on comprehensively drugging the tumor-immune synapse with combinations of human monoclonal antibodies, multiclonals, and engineered protein constructs. compass is industrializing antibody discovery and decentralizing biologic validation through a partnership-first mentality that leverages best-in-class technologies and top-tier academic laboratories around the world. novel scientific insights are validated and explored deeply inside our labs before compass pursues the best proprietary combinations of therapeutics into human clinical trials. in 2015, compass quietly closed a $120mm series a financing to fund our ambitious plan to build a fully-integrated biopharmaceutical company from the ground up. our investors are among the most sophisticated venture capitalists in the industry who exemplify our philosophy of building long term economic value only by delivering therapeutics with meaningful efficacy beyond

Exchange

NASDAQ

$M

Total Revenue

35

Employees

$262M

Market Capitalization

-4.81

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $CMPX News

CMPX Compass Therapeutics, Inc.

1d ago, source: Seeking Alpha

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States.

With 52% ownership of the shares, Compass Therapeutics, Inc. (NASDAQ:CMPX) is heavily dominated by institutional owners

16d ago, source:

Key Insights Significantly high institutional ownership implies Compass Therapeutics' stock price is sensitive to ...

Compass Therapeutics: A Strong Buy on Promising Clinical Pipeline and Strategic Milestones

3d ago, source:

Leerink Partners analyst Andrew Berens has maintained their bullish stance on CMPX stock, giving a Buy rating on March 21. Andrew Berens has ...

Compass Therapeutics’ Strategic Advancements and Strong Financials Prompt Buy Rating

7d ago, source:

Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Compass Therapeutics (CMPX – Research Report), with a price target ...

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

7d ago, source: Stockhouse

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to ...

Compass Therapeutics Inc Ordinary Shares

27d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

28d ago, source: Yahoo Finance

BOSTON, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics ...

Compass Therapeutics to be Added to the Russell 2000® and Russell 3000® Indexes

27d ago, source: ADVFN

Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases ...

Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update

7d ago, source: Morningstar

BOSTON, March 21, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ...

Compass Therapeutics Inc.

28d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...